Balch, Jeremy A.
Chen, Uan-I
Liesenfeld, Oliver
Starostik, Petr
Loftus, Tyler J.
Efron, Philip A.
Brakenridge, Scott C.
Sweeney, Timothy E.
Moldawer, Lyle L.
Funding for this research was provided by:
National Institute of General Medical Sciences (T32 GM008721-24, RM1 GM139690-02)
Research Subcontract: Inflammatix Inc and University of Florida (75A50119C00044)
U.S. Army Medical Research Acquisition Activity
U.S. Department of Health and Human Services
Biomedical Advanced Research and Development Authority
Article History
Received: 28 April 2023
Accepted: 7 July 2023
First Online: 20 July 2023
Declarations
:
: Ethics approval was obtained from the University of Florida Institutional Review Board (#201702261 and #201400611). Informed consent was obtained from each subject or their surrogate decision-maker. Self-reported or proxy-reported race and ethnicity category data were collected as per National Institutes of Health reporting guidelines and requirements.
: Not applicable.
: Dr. Balch reported receiving Grants from the National Institute of General Medical Sciences during the conduct of the study. Drs. Chen, Liesenfield, and Sweeney reported being an employee and stock option holder of Inflammatix Inc during the conduct of the study, and outside the submitted work. Dr. Starostik reported funding from the U.S. Army Medical Research Acquisition. Drs. Loftus and Efron reported receiving Grants from the National Institute of General Medical Sciences during the conduct of the study. Dr. Brakenridge reported receiving joint academic-industry Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) funding from Inflammatix Inc during the conduct of the study. Dr. Sweeney reported receiving Grants from BARDA Division of Research, Innovation, and Ventures (DRIVe); being an employee and shareholder during the conduct of the study and outside the submitted work; and being the licensed inventor on several patents pending and issued that cover the IMX-SEV metric. Dr. Moldawer reported a subcontract on BARDA Grant to Inflammatix Inc during the conduct of the study and receiving grants from the National Institute of General Medical Sciences. No other disclosures were reported.